



#### **FORENOTE**

All 2013 data are restated for comparison purposes for the Group's application of IFRS 11 effective January 1st 2014.

Furthermore, Solvay presents Adjusted Income Statement performance indicators that exclude non-cash Purchase Price Allocation (PPA) accounting impacts related to the Rhodia acquisition.

### **Sustained Earnings growth momentum**



#### **Solid demand dynamics**

- Particularly at innovation-driven Growth engines
- Strong Chemlogics contribution



Strong operating leverage offset forex headwinds and CER phase out



#### **Excellence programs momentum continued**

- Sustained pricing power
- Fixed cost inflation offset



All operating segments contributing to profit expansion

# Strong set of results

- REBITDA +10% YoY
- Margin
   +140bp
   to 18.4%





### **Strong set of results**

#### Q2 2014 financial highlights

€2.6 bn

+2% yoy

€ 148 m

in 2013

**Net Sales** 

- 7 Organic volume growth, despite CER phase-out
- → Stable pricing
- → Forex headwinds

€(292) m

**Net Income** 

Adjusted, Group share

- → Lower non-recurring costs
- 7 Debt optimization led to lower cost of carry but offset by one-off HSE discounting charges
- Impairment related to Inovyn™ € (422) m (mainly non-cash)

€485 m

**REBITDA** 

+10% YOY

- → Solid demand dynamics further strengthened by excellence momentum

  - Inflation of fixed costs offset
- → Forex headwinds

€89 m **FCF** 

+40% VOV

→ In line with seasonal patterns



# Strategic portfolio management pursued Initiated divestitures nearing completion

### Chlorovinyls exit

#### Inovyn™ JV creation by YE 2014

- Conditional approval received from EU anti-trust authorities
- Binding deal reached with JV partner Ineos
  - Simplified terms
  - Large part of targeted cash proceeds secured upfront
  - Exit after 3 years
- JV creation expected by YE 2014

#### Benvic sale closed

Sold to OpenGate in June 2014

#### Indupa sale to Braskem progressing

 Awaiting approval from Brazilian anti-trust authorities before YE 2014

### **Eco Services exit**


#### Sale to CCMP Capital


- Sulphuric acid virgin production and regeneration business in US
- Binding agreement reached with CCMP Capital
- EV of US\$ 890 m
- EV/EBITDA\* just over 8.0x
- \* LTM as of June 2014

# Redeployment for Value



# Demand and excellence momentum underpinning solid REBITDA growth despite headwinds





Organic volume growth despite CER phase-out. Sales of €44 m in Q2 2013

Strong Chemlogics contribution Forex headwinds primarily from USD, BRL, THB, CNY and JPY

Operating results underpinned by demand and Excellence programs

- Sustained pricing power
- Inflation of fixed costs offset

REBITDA margin increased by 140 bp



### **Broad performance delivery across businesses**





Strong Chemlogics and volume growth largely offset forex and weak performance in Coatis

Record performance underpinned by innovation-driven volume growth and operational efficiency



**Advanced Formulations** 



36%

**Advanced Materials** 

**Performance Chemicals** 

### **Functional Polymers**



Improved demand and strong manufacturing excellence program delivery

Pricing power and volume growth offset by fixed cost inflation and forex





<sup>\*</sup> Excluding Corporate & Business Services

### Result form continued operations increased by 31%

#### **Adjusted Profit & Loss statement**

in€m	Q2 2014	Q2 2013
Net sales	2,640	2,582
REBITDA	485	440
Other elements	11	(1)
Depreciation & Amortization	(160)	(155)
REBIT	337	284
Non-recurring items	(46)	(97)
EBIT	291	187
Net financial charges	(75)	(51)
Income taxes	(65)	(20)
Result from continuing operations	150	115
Result from discontinued operations	(481)	48
Net income Solvay share	(292)	148

#### Other elements

- €13 m impact of Ruble evaluation on debt Rusvinyl
- € (2) m holdback payments at Chemlogics

#### **Non-recurring costs**

Restructuring costs of € (13) m, significantly down on Q2 2013

#### **Net financial charges**

- Net debt charges fell € (11) m thanks to debt optimization
- Discounting costs for environmental provisions up € (30) m as rates down 50 bp in Eurozone, compared to upward move in Q2 2013 in Nafta and Mercosur.

#### **Income taxes**


- Nominal tax rate of 33% (34% underlying)
- Taxes Q2 2013 at low level due to non-recurring elements

#### **Discontinued operations**

€ (422) m impairment, Solvay share, related to Inovyn<sup>™</sup>



# Net debt increase in line with seasonal dividend and interest payment patterns



Working capital uptake in a context of demand dynamics and planned maintenance turn-arounds


Concentration of interest payments in Q2. Includes € (50) m of one-offs related to early HY bond repayment


Payment of dividend balance and 1<sup>st</sup> hybrid coupon of € (15) m



<sup>\*</sup> Net debt excludes hybrid bonds of €1.2 bn booked as equity

# Working Capital needs in line with demand dynamics and industrial cycle











### Selective investments for value









### Larger on-going investment projects

**Novecare** Specialty Surfactants plant in Germany **Aroma Performance** Vanillin plant in China **Specialty Polymers** Fluoro-polymers JV with 3F **HDS** plant in Poland 85 ktonnes/year PVC plant in Russia (in JV with Sibur) Expected Rusvinyl\* 330 ktonnes/year commissioning Large-scale alkoxylation plant in Texas, USA **Novecare** Large-scale alkoxylation plant in Singapore **Specialty** 

2015
Expected commissioning

Polymers

> Fluoro-polymers plant in China

Peroxide

> HPPO plant in Saudi Arabia
300 ktonnes/year

Bicarbonate plant in Thailand 100 ktonnes/year


Soda Ash &

**Derivatives** 



<sup>\*</sup> Reported as equity investment

### A sound and more efficient balance sheet




#### Strong credit ratios (30/06/2014)



#### **Optimising Balance Sheet efficiency**

in €bn



#### Repayments in 2014-2015 → €1.8 bn

Early redemption of high-yield (HY) bonds

- ⇒ Average interest rate reduced by 40 bp to 4.9%
- ⇒ Cost of carry halved to € (50) m by 2015



### 2014 outlook re-iterated

# Encouraging H1 underpins confidence

Solvay expects
high single-digit
REBITDA growth
at current perimeter\*
& prevailing forex
exchange rates

\* Reflects eventual restatement in 2013 and 2014 reference periods for the discontinuation of Eco Services



### **Transformation continues**



- Complete initiated portfolio upgrades
- Grow with our customers
- Sustain focus on excellence
- Deliver profit growth

### **Asking more from chemistry**



### **Take-aways**







On track towards

**REBITDA** to reach €2.3 – 2.5 bn\*

REBITDA margin to reach 18%

\* At constant perimeter

2016

**CFROI** to increase by > 100 bp vs 2013\*\*

> 2/3 of businesses in value-creation zone

> > \*\* Prior to discontinued operations



### Safe harbour

To the extent that any statements made in this presentation contain information that is not historical, these statements are essentially forward-looking. The achievement of forward-looking statements contained in this presentation is subject to risks and uncertainties because of a number of factors. including general economic factors, interest rate and foreign currency exchange rate fluctuations; changing market conditions, product competition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals; regulatory approval processes, all-in scenario of R&D projects and other unusual items.

Consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "believes," "may," "could" "estimates," "intends", "goals", "targets", "objectives", "potential", and other words of similar meaning. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update any forward-looking statements.



### Annexes

- Additional Q2 and H1 2014 financial data
- Additional FY 2014 considerations
- 2016 ambitions
- Segment presentation



### **Balance sheet**

### **Q2 Cash flow statement**

in€m	30/06/2014	31/12/2013
Fixed assets	9,780	9,732
Investment & shares	825	735
Loans & other non current financial receivables / payables	23	84
Assets held for sale	1,195	1,621
Taxes payable/receivable + Others	89	44
Working capital	1,578	1,259
Total invested capital	13,490	13,475
Equity	6,884	7,453
Provisions	4,018	3,820
Dividends	(2)	112
Net financial debt	1,644	1,142
Liabilities related to assets held for sale	946	949
Total financing	13,490	13,475

in€m	Q2 2014	Q2 2013
Cash flow from operating activities	293	212
Cash flow from investing activities	(289)	(163)
Cash flow from financing activities	(85)	(359)
Net change in cash & cash equivalents	(81)	(311)
Currency translation differences	(1)	(46)
Opening cash balance	1,193	1,614
Ending cash balance	1,111	1,258
Free Cash Flow	89	64
From continuing operations	98	10
From discontinued operations	(9)	54



### **H1 Income statement**

(adjusted)


in€m	H1 2014	H1 2013
Net sales	5,192	5,098
REBITDA	953	862
Other elements	(5)	-
Depreciation & Amortization	(321)	(310)
REBIT	626	552
Non-recurring items	(76)	(137)
EBIT	551	415
Net financial charges	(173)	(135)
Income taxes	(118)	(76)
Result from continuing operations	260	204
Result from discontinued operations	(470)	60
Net income Solvay share	(186)	235


### **H1 Cash flow statement**

in€m	H1 2014	H1 2013
Cash flow from operating activities	390	357
Cash flow from investing activities	(511)	(332)
Cash flow from financing activities	(738)	(526)
Net change in cash & cash equivalents	(859)	(501)
Currency translation differences	(3)	(28)
Opening cash balance	1,972	1,787
Ending cash balance	1,111	1,258
Free Cash Flow	(8)	53
From continuing operations	(61)	(122)
From discontinued operations	53	175



# Demand and excellence momentum underpinning REBITDA growth





Organic volume growth despite CER phase-out. Sales of €58 m in H1 2013

Strong Chemlogics contribution Forex headwinds primarily from USD, BRL, THB, CNY and JPY

Operating results underpinned by demand and Excellence programs

- Sustained pricing power
- Inflation of fixed costs offset


REBITDA margin increased by 140 bp



### Net debt increase in line with seasonal patterns

#### Net debt\* evolution

in € m



Working capital uptake in a context of demand dynamics and planned maintenance turn-arounds

Concentration of interest payments in H1. Includes € (50) m of one-offs related to early HY bond repayment


Payment of dividend balance and 1<sup>st</sup> hybrid coupon of € (15) m




<sup>\*</sup> Net debt excludes hybrid bonds of €1.2 bn booked as equity

### Lower rates led to slight pension liability increase

All presented figures are for continued operations only





### Net pension liability denominated for 76% in EUR

#### Discount rates\* decreased

	31/12/2013	30/06/2014	change
EUR	3.25%	2.75%	-0.50%
GBP	4.50%	4.25%	-0.25%
USD	4.75%	4.25%	-0.50%
Weighted average	3.88%	3.50%	-0.38%

#### Pension assets of €2,022 m by 30/06/2014

- 50% Equities / Diversified alternative funds
- 50% Bonds / Real estate

### Cash contribution in H1 2014 of €(86) m, vs €(81) m in H1 2013

<sup>\*</sup> Average discount rate on post employment benefit related liabilities applicable to high quality corporate bonds in EUR, GBP and USD zones



### Annexes

- Additional Q2 and H1 2014 financial data
- Additional FY 2014 considerations
- 2016 ambitions
- Segment presentation



### **REBIT(DA)** considerations for 2014

#### **Forex impact**

- FY YoY impact expected of € (60) (65) m at prevailing rates
- H1 YoY impact of € (53) m
- More than half conversion, rest transactional
- Mainly linked to USD, JPY and BRL

#### Rusvinyl ramp-up

- PVC JV in Russia
- Pre-operational charges linked to impact on JV debt of ruble/euro fluctuation with H1 impact of €2 m
- Planned commissioning and subsequent ramp-up in H2

#### **CERs (Carbon Emission Rights)**

- Scheme phased out in H1 2013
- FY YoY sales impact of €(58)m, taken in H1

#### **Eco Services**

Sale closing expected before YE 2014

#### **Chemlogics effects**

- Acquisition consolidated since 01/11/2013
- H1 PPA inventory impact + holdback payments for € (7) m
- Going forward only holdback payments of
   ~ € (2) m per quarter until 2016



### Financials considerations for 2014

#### **Cost of net indebtedness**

- Debt repayments
  - € 1,300 m in H1 2014 (including HY bonds)
  - €500 m in June 2015
- Lead to a reduction of net interest charges
  - Average gross interest rate to reduce by 40 bp to 4.9% vs 2013
  - Cost of carry to halve
  - FY P&L cost expected at ~ €140 m

#### **Discounting cost on provisions**

- Recurring FY cost of € (120) (130) m, provided no change in discount rates\* during year
- Additional one-off charges in H1 of € (29) m from impact of discount rates decrease on environmental provisions
- Average discount rate on environmental provisions based on 10-year government bonds in EUR, GBP, USD and BRL zones

#### **Hybrid bond**

- Nominal value of € 1.2 bn
- Initial average dividend yield of 4.7%
  - € 0.7 bn at 4.199%
  - € 0.5 bn at 5.425%

- Accounting considerations
  - Income statement
    - → No impact
  - Balance sheet
    - → Treated under Equity
  - Cash flow statement
    - → Dividends treated in CF from financing

- Dividend cash-out
  - Q2 2014: €(15) m
  - Q4 2014: € (27) m
  - Q2 2015: € (29) m
  - Q4 2015: €(27) m
    - . . .



### Other considerations for 2014

#### **Depreciation & amortization**

- Recurring Depreciation & Amortization
  - H1 cost of € (321) m
  - FY cost expected of ~ € (650) m
- Rhodia PPA impact
  - H1 impact of €58 m
  - FY impact expected of ~ € 115 m

#### **Discontinued operations**

- Expected to reach completion in 2014
- Indupa sale to generate ~ € (60) m\* currency translation adjustments at deal closing
- Chlorovinyls JV with Ineos will be treated as recurring equity investment upon JV effectiveness
- \* Situation as of 30/06/2014

#### **Underlying tax rates**

- Progressing from mid to low 30s over 2014-2016
- Underlying tax rate excludes non-recurring elements

#### **Non-recurring elements**

- Restructuring costs
- HSE provisions on non-operational sites
- Portfolio management-related gains & losses
- Contingencies / litigations



### Annexes

- Additional Q2 and H1 2014 financial data
- Additional FY 2014 considerations
- 2016 ambitions
- Segment presentation



### Solvay, a major global chemical player

€10.0 bn

**Net Sales** 

€1.7 bn

17%
REBITDA margin

€378 m

Adjusted Net Income, Group share

Restated for IFRS 11 application as from 01/01/2014 Adjusted: Excluding non-cash PPA accounting impacts related to the Rhodia acquisition

### **Based on strengths**



Well-balanced geographical spread and end-user markets



Leading player in 90% of our businesses



Strong R&I portfolio

### And with ambition

2013 figures

**117** 

Industrial sites

15

Major R&I centers

29,400

Employees (EFTEs)

56


Country presence

Non-financial figures exclude discontinued operations, except for employees



# Well-balanced geographical spread and end-user markets

Balanced geographic exposure\*



## **Exposure to**higher growth end-markets\*





<sup>\*</sup> Figures represent % of 2013 net sales (pro-forma Chemlogics)

### 90% of our business ranking among top 3 players

1


ADVANCED FORMULATIONS	Specialty surfactants	PERFORMANCE CHEMICALS	Hydrogen peroxide
	Diphenols		Soda ash
	Phosphorus chemistry		Bicarbonate
ADVANCED MATERIALS High-performance engineering polymers & compounds	Fluorinated polymers	Rare earth formulations	
		High-barrier polymers	High-dispersible silica

3





# Strong innovation portfolio aligned with global megatrends



### **Converting vision into value**

#### **Our vision**

- Build a strong global leader in the chemical industry
- Be a model of sustainable chemistry
- Become a high growth, less capital intensive
   & high return Group

### **Our strategy**

- Reinforcing business profile through strategic portfolio changes
- Striving for excellence across businesses
- Innovating to create sustainable solutions
- Transforming company culture with a focus on performance

#### Our 2016 ambition

**REBITDA** to reach €2.3 – 2.5 bn\*

REBITDA margin to reach 18%

**CFROI** to increase by >100 bp vs 2013\*\*

2/3rd of businesses in value-creation zone

Being a model of sustainability

Reducing our impact on environment

\* At constant perimeter \*\* Prior to discontinued operations




### A business portfolio change

#### **Executing our strategic action plan**

**2010**Pharma divestiture

**2011**Rhodia acquisition

#### To enhance our business profile



2012

#### **INTEGRATION**

Integration & definition of new strategic priorities

Alignment of corporate & business structure

Renew management And people model 2013

#### **TRANSFORMATION**

Chlorovinyls Europe JV announcement

Solvay Indupa divestiture

Chemlogics acquisition

#### LAUNCHING EXCELLENCE INITIATIVES


Polyamide breakthrough performance improvement plan

Soda Ash breakthrough performance improvement plan




### **REBITDA** growth

### supported by strong operational levers






# Enhanced quality of earnings across segments with differentiated levers throughout our businesses






# Unlocking value by increasing CFROI and REBITDA margin





Bubble Size indicates REBITDA (in  $\in$  bn)



Premium return = WACC + 150bp



# Focused on being a model of sustainability taking commitments



- Reach excellence in safety & health
- Deploy unmatched sustainable portfolio management
- Reduce our impact on environment by 2020



- Manage risk
- Develop rich & balanced social dialogue







### **Providing sustainable solutions**



# **Executing a clear value creation strategy**

Towards a higher growth, improved cash generation & enhanced returns
Chemical Group



Targeting Sustainable Value Growth






# Annexes

- Additional Q2 and H1 2014 financial data
- Additional FY 2014 considerations
- 2016 ambitions
- Segment presentation




# **Organization set-up**



Customer-centric Empowered Entrepreneurial Result-oriented



# **Organized in Global Business Units**



<sup>\*</sup> Restated for IFRS 11 application as from 01/01/2014

<sup>\*\*</sup> To be exited by YE 2014




### **Advanced Formulations**

**2013** Figures

**€2,432 m** Net Sales

**€369 m** REBITDA












As one of Solvay's growth engines, the businesses grouped under Advanced Formulations stand out for their innovation capacity and low capital intensity. Their offerings address major societal trends, meeting ever stricter requirements to respect the environment, save energy and challenges of the mass consumer markets.



# **Advanced Formulations 2014 Q2 performance**

Strong Chemlogics and volume growth largely offset forex and weak performance in Coatis



#### **REBITDA**

Aroma Performance

H1 2014

€221 m

8% yoy Q2 2014

€119 m



#### **Novecare**

- Good dynamics in Oil & Gas market through customer recognition of Solvay's product portfolio and capabilities
- Chemlogics ramping up business and at record profitability
- Agro market suffered from short season in US
- Growth in HPC market offset by lower prices
- Forex impact weighs on yoy comparison

#### **Coatis**

- Uncompetitive domestic LatAm market weighed on performance
- Excellence measures mitigated increased cost level


#### **Aroma Performance**

- Positive market trends overall in Aroma ingredients and Inhibitors
- Gradual recovery from Force Majeure (in Q1)



### **Novecare**

Cutting-edge technologies in diversified focused markets






### **Advanced Materials**

2013 Figures

**€2,551 m**Net Sales

**€646 m** REBITDA













A leader in markets with high entry barriers and strong returns on investment, the Advanced Materials segment is a major contributor to the Group's performance and growth. Innovation, its global presence feature and long-term partnerships with customers provide a compelling competitive edge with industries seeking increasingly energy efficiency and less polluting functionalities.



# **Advanced Materials 2014 Q2 performance**

Record performance beat underpinned by innovation-driven volume growth and operational efficiency



H1 2014

€1,3<mark>29 m</mark>


2% yoy

Q2 2014

€670 m

2% yoy

- Specialty Polymers
- Silica
- Rare Earth Systems
- Special Chemicals



#### **REBITDA**

H1 2014

€362 m

15% yoy

Q2 2014

€187 m



### **Specialty Polymers**

- Volume growth across all regions and most end markets
- Demand momentum in Automotive, Industrial and Electrical & Electronics markets continued
- New product launch boosted Smart devices market

#### **Silica**

Strong demand in Europe (both OEM and replacement)

#### **Rare Earth Systems**

 Volumes and margins underpinned by new regulation in catalyst business


### **Special Chemicals**

- Good business trends in most end-markets, esp. automotive and (micro-)electronics
- Margin improvement thanks to business portfolio refocus



# **Specialty Polymers**


### Focused on the most advanced products





# **Specialty Polymers**

Industry leader with the broadest product portfolio




Broadest portfolio + Innovation leader = Best solution provider



### **Silica**

### Highly Dispersible Silica (HDS) delivers value to the tire industry





Enables a 5-7% improvement in efficiency

... growing across a number of applications

### In passenger car and light trucks

- **Energy-efficient tires**
- Winter tires
- Sport tires

### In heavy trucks

Commercial emergence of tires using a majority of silica vs. carbon black


HDS, a significant enabler of performance, a minor portion of overall tire production cost (<3%)




### **Performance Chemicals**

**2013** Figures\*

**€3,189 m** Net Sales **€766 m** REBITDA















Operating on mature resilient markets, this Segment's success is based on economies of scale, competitiveness and quality of service. Solidly cash-generating, the Performance Chemicals businesses are engaged in new programs of excellence to create additional sustainable value.


\*\* To be exited by YE 2014



<sup>\*</sup> Restated for IFRS 11 application as from 01/01/2014

# Performance Chemicals 2014 Q2 performance

Pricing power and volume growth offset by fixed cost inflation and forex



#### **REBITDA**

H1 2014

€377 m

6% yoy

Q2 2014

€189 m



#### Soda Ash & Derivatives

- Demand up in Europe and export market up
- US production affected by logistics disruption
- Prices up overall
- Adverse yoy effect from lower USD

#### **Peroxide**

- Rising demand for peroxide in EU and US
- Fixed costs level up due to prolonged maintenance

#### **Acetow**

• Higher sales prices and strong industrial performance

#### **Eco Services**

Volume growth offset by forex


#### **Emerging Biochemicals**

 Tough conditions persist and heavy impact from lower Thai Baht



### **Soda Ash & Derivatives**

Cost is a key success factor in the soda ash industry



Soda ash plants

Source, Solvay based on external databases



### **Soda Ash & Derivatives**

European soda ash supply/demand to improve in next 3 years

#### 2014-2016

# **Restructuration** started with **closure** announcements

- Solvay Povoa (0.2 mt/yr)
- Tata Winnington (0.5 mt/yr)

# Production capacity utilization rate to increase

- Following restructuring at the supply side
- Following slight expected growth in demand

#### Kazan project

Potentially adding 2.5 mt/yr production capacity

2017-2019

- Based on natural production process
- Cash cost expected at same level as best-in-class European synthetic assets

Further **restructuring** among least competitive assets in the European industry can be expected




# **Functional Polymers**

2013 Figures

**€1,763 m** Net Sales

€93 m REBITDA













The key success factors of this Segment, which primarily groups the Polyamide activities, are continuous manufacturing optimization and innovation. Solvay is one of the few players to operate across the entire polyamide 6-6 chain.

# **Functional Polymers 2014 Q2 performance**

Improved demand and strong manufacturing excellence program delivery



H1 2014

€896 m

(6)% yoy


Q2 2014

€448 m

(7)% yoy

■ Polyamide

Chlorovinyls



#### **REBITDA**

H1 2014

€78 m

28% yoy

Q2 2014

€38 m



#### **Polyamide**

- · Volume growth in Europe and Asia
- Weakness of Fibras market in LatAm continues.
- Delivery on excellence programs has positive impact on margins

### **Chlorovinyls**

- Benvic sold to OpenGate
- Indupa being sold to Braskem (discontinued)
- European chlorovinyls to be contributed to Inovyn<sup>™</sup> JV (discontinued)
  - Net sales: € 465 m; REBITDA: € 20 m
  - Difficult market environment with low price and weak margin



# **Corporate & Business Services**

**2013** Figures

**€67 m** Net Sales **€(169) m** REBITDA





This Segment includes the Solvay Energy Services business which delivers energy optimization programs in the Group and for third parties. It also includes the corporate functions.

### 2014 Q2 performance

Tight cost control partially offset phased-out CER sales





### **Energy Services**

- No material REBITDA contribution
- CER phase-out in H1 2013 affecting comparables

### Other Corporate & Business Services

- Tight cost control on corporate structure and functions
- Phasing of certain corporate programs
- Positive forex impact



SOLVAY
asking more from chemistry®

www.solvay.com